Recent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Eli Lilly’s Zepbound led to 47% greater weight loss than Wegovy in a 72-week trial, yet retail sentiment turned bearish on ...

Willie Rioli returned to training at Alberton on Monday, in an encouraging sign that he will be ready to return to Port ...